Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
Abstract Background The World Health Organization (WHO) recommends that the cost effectiveness of introducing human papillomavirus (HPV) vaccination is considered before such a strategy is implemented.However, developing countries often lack the technical capacity to perform and interpret results of economic appraisals of vaccines.To provide inform